Z-D-丙氨酸-OSu | 27167-53-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Z-D-丙氨酸-OSu
• 中文别名: N-苄氧羰基-D-丙氨酸-2,5-二氧代-1-吡咯烷酯；苄氧羰基-D-丙氨酸N-羟基琥珀酰亚胺酯
• 英文名称: N-(benzyloxycarbonyl)-D-alanine N-hydroxysuccinimide ester
• 英文别名: N-benzyloxycarbonyl-D-alanine N-hydroxysuccinimido ester；benzyloxycarbonyl-D-alanine-N-hydroxy-succinimide ester；CBZ-D-alanine N-hydroxysuccinimidate ester；N-CBZ-D-Ala-N-hydroxysuccinimide；Z-D-Ala-OSu；N-benzyloxycarbonyl-D-alanine N-hydroxysuccinimide ester；(2,5-dioxopyrrolidin-1-yl) (2R)-2-(phenylmethoxycarbonylamino)propanoate
• CAS: 27167-53-9
• 化学式: C₁₅H₁₆N₂O₆
• 分子量: 320.302
• InChiKey: OFIYNISEFIEQBC-SNVBAGLBSA-N

物化性质

• 密度：
  1.36

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2925190090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-D-Ala-osu
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-D-Ala-osu
CAS number: 27167-53-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C15H16N2O6
Molecular weight: 320.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Z-D-丙氨酸-OSu 在 sodium hydroxide 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 4.5h， 生成 Z-D-Ala-DL-Ama(OBzl)-OH
  参考文献：
  名称：

  Ariyoshi; Hasegawa; Ota, Agricultural and biological chemistry, 1990, vol. 54, # 7, p. 1623 - 1630

  摘要：

  DOI：
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 N-benzyloxycarbonyl-D-alanine 在 N,N'-二环己基碳二亚胺 作用下， 以 乙腈 为溶剂， 反应 12.5h， 以85%的产率得到Z-D-丙氨酸-OSu
  参考文献：
  名称：

  [EN] SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE
  [FR] PROCÉDÉ DE PRÉPARATION D'ÉTELCALCÉTIDE EN PHASE SOLUBLE

  摘要：

  该即时披露涉及用于制备etelcalcetide及其药用可接受盐的溶液相片段偶联方法。

  公开号：

  WO2016154580A1

文献信息

• 7-Azetidinylquinolones as Antibacterial Agents. 3. Synthesis, Properties and Structure-Activity Relationships of the Stereoisomers Containing a 7-(3-Amino-2-methyl-1-azetidinyl) Moiety
  作者：Jordi Frigola、David Vano、Antoni Torrens、Angels Gomez-Gomar、Edmundo Ortega、Santiago Garcia-Granda

  DOI：10.1021/jm00007a017

  日期：1995.3

  de]-1,4-benzoxazine-6-carboxylic acids was synthesized to study the effect of the azetidine moiety on tricyclic quinolone antibacterial agents. A series of amino acid prodrugs of chiral naphthyridines 24a and 24b and quinolone 33a (cetefloxacin) was prepared and evaluated for antibacterial activity, solubility, and pharmacokinetic behavior. The absolute configuration of the new azetidinylquinolones

  一系列立体化学纯的7-（3-氨基-2-甲基-1-氮杂环丁烷基）-1,4-二氢-6-氟-4-氧代喹啉-和-1,8-萘啶-3-羧酸制备了位于1、5和8位的取代基，以确定手性相对于外消旋混合物的效价和体内功效的影响（第2部分，参见：J. Med.Chem。1994，37， 4195-4210）。一系列手性9-氟-2,3-二氢-3-甲基-7-氧-10-（取代的1-氮杂环丁烷基）-7H-吡啶[1,2,3-de] -1,4-苯并恶嗪合成-6-羧酸以研究氮杂环丁烷部分对三环喹诺酮抗菌剂的作用。制备了一系列手性萘啶24a和24b以及喹诺酮33a（cetefloxacin）的氨基酸前药，并评估了其抗菌活性，溶解度和药代动力学行为。通过对拆分的氮杂环丁醇（15）和化合物25a（E-4767）的一种非对映异构盐进行X射线分析，可以确定新的氮杂环丁烷基喹诺酮类化合物的绝对构型，该化合物在体外和体内的总体情况最佳。
• Tripeptides and sweetening agents containing the same
  申请人：Ajinomoto Co., Inc.

  公开号：US04780528A1

  公开（公告）日：1988-10-25

  Tripeptide sweeteners represented by formula (I) X--Asp--Y--OR wherein X is glycine or a D or DL-isomer of alanine, .alpha.-aminobutyric acid, serine, threonine, norvaline, asparagine, B-methyl aspartate, proline or pipecolic acid, and Y is a D, L or DL-isomer of alanine, phenylalanine, phenylglycine, serine or .beta.-aminobutyric acid or a salt thereof, and R is methyl, ethyl, propyl or isopropyl, are disclosed.

  三肽甜味剂的化学式(I) X--Asp--Y--OR中，其中X是甘氨酸或丙氨酸的D或DL异构体，α-氨基丁酸，丝氨酸，苏氨酸，正异戊氨酸，天冬酰胺，B-甲基天冬酸，脯氨酸或吡啶环氨酸，Y是丙氨酸，苯丙氨酸，苯基甘氨酸，丝氨酸或β-氨基丁酸的D，L或DL异构体或其盐，R是甲基，乙基，丙基或异丙基。
• Synthesis of N-α-aminoacyl derivatives of melphalan for potential use in drug targeting
  作者：Dale W. Larden、H.T.Andrew Cheung

  DOI：10.1016/0040-4039(96)01665-6

  日期：1996.10

  N-L- and D-alanyl derivatives (9a, 9b) of melphalan (1) have been synthesized in eight steps (9a, 22%; 9b, 18% overall yield) from p-nitro-L-phenylalanine.

  从对-硝基-L-苯丙氨酸以八步（9a，22％；9b，总收率18％）合成了melphalan（1）的NL-和D-丙氨酰基衍生物（9a，9b）。
• Comparison of Cyclodextrin-Dipeptide Inclusion Complexes in the Absence and Presence of Urea by Means of Capillary Electrophoresis, Nuclear Magnetic Resonance and Molecular Modeling
  作者：Benjamin Waibel、Josef Scheiber、Claudia Meier、Manuela Hammitzsch、Knut Baumann、Gerhard K. E. Scriba、Ulrike Holzgrabe

  DOI：10.1002/ejoc.200700052

  日期：2007.6

  using Ala-Phe and Ala-Tyr as model compounds. For this purpose three different analytical methods were employed: capillary electrophoresis (CE), 1H-NMR spectroscopy and molecular dynamics simulations (MD). Electropherograms of the peptide enantiomers were different in the presence and absence of urea. For example, at pH 2.5 in the absence of urea the enantiomers of Ala-Tyr are not separated in contrast

  用环糊精 (CD) 修饰的毛细管电泳 (CE) 用于分离肽的立体异构体的用途已得到充分证实。为了增加 β-CD 的溶解度，通常将尿素添加到缓冲液中，这可能会影响 CD 与客体分子的复合。本研究的目的是使用 Ala-Phe 和 Ala-Tyr 作为模型化合物研究尿素对二肽和 β-CD 之间络合的影响。为此，采用了三种不同的分析方法：毛细管电泳 (CE)、1H-NMR 光谱和分子动力学模拟 (MD)。存在和不存在尿素时，肽对映异构体的电泳图有所不同。例如，在不存在尿素的情况下，在 pH 2.5 时，与使用含有尿素的缓冲液相比，Ala-Tyr 的对映异构体不会分离。在 NMR 光谱和旋转框架 Overhauser 增强光谱 (ROESY) 中应用“络合诱导化学位移 (CICS)”揭示了在不存在和存在尿素的情况下 β-CD 对肽对映体络合的差异，表明复合物通过酪氨酸的酚羟基。对不同配合物进行了 MD
• Neue Diphosphonsäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：EP0197478A1

  公开（公告）日：1986-10-15

  Diphosphonsaeure-Derivate der allgemeinen Formel I in der R1, R2, R3, R4 und R5 jeweils unabhaengig voneinander oder auch gemeinsam Wasserstoff oder neideres Alkyl bedeuten, wobei R, und X bzw. R3 und Y bzw. R4 und Z zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen Fuenf-oder Sechsring bilden koennen, X und Y jeweils unabhaengig voneinander eine geradkettige oder verzweigte Alkylenkette mit 1-6 Kohlenstoffatomen, die gegebenfalls durch Aromaten oder Heteroaromaten substituiert sien kann, Z eine geradkettige oder verzweigte Alkylenkette mit 1-6 Kohlenstoffatomen, die durch Heteroatome unterbrochen und gegebenenfalls auch durch Aromaten oder Aromaten oder Heteroaromaten substituiert sien kann, n = 0-2 und A = Wasserstoff oder Hydroxy bedeuten, sowie deren pharmakologisch unbedenkliche Salze, Verfahren zu ihrer Herstellung sowie Arzneimittel, die diese Verbindungen enthalten zur Behandlung von Calciumstoffwechselstoerungen.

  通式 I 的二膦酸衍生物 其中 R1、R2、R3、R4 和 R5 各自独立或共同为氢或低级烷基，其中 R 和 X 或 R3 和 Y 或X和Y各自独立地代表具有 1-6 个碳原子的直链或支链亚烷基链，可任选被芳香族化合物或杂芳香族化合物取代，Z代表具有 1-6 个碳原子的直链或支链亚烷基链、n＝0-2，A＝氢或羟基，以及其药理学上可接受的盐、制备工艺和含有这些化合物的用于治疗钙代谢紊乱的药物。